Literature DB >> 12064892

Adult polycystic ovary syndrome begins in childhood.

Stephen Franks1.   

Abstract

Polycystic ovary syndrome (PCOS) frequently presents during adolescence and is the commonest cause of menstrual irregularity and hirsutism. The characteristic endocrine abnormalities include hypersecretion of androgens and LH. Metabolic dysfunction is also a feature of many young women with PCOS. Hyperinsulinaemia and insulin resistance, which can be regarded as an exaggeration of the normal metabolic changes that occur during puberty, are further amplified by obesity. The aetiology of PCOS is uncertain but there is evidence for a primary abnormality of ovarian androgen production which is manifest at puberty but may have its origins in childhood or even during fetal development. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 12064892     DOI: 10.1053/beem.2002.0203

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  28 in total

1.  Prenatal testosterone exposure leads to hypertension that is gonadal hormone-dependent in adult rat male and female offspring.

Authors:  Vijayakumar Chinnathambi; Meena Balakrishnan; Chandrasekhar Yallampalli; Kunju Sathishkumar
Journal:  Biol Reprod       Date:  2012-05-03       Impact factor: 4.285

2.  Interventional studies for polycystic ovarian syndrome in children and adolescents.

Authors:  Patricia Myriam Vuguin
Journal:  Ped Health       Date:  2010-02

3.  Hyperandrogenemia in obese peripubertal girls: correlates and potential etiological determinants.

Authors:  Karen L Knudsen; Susan K Blank; Christine Burt Solorzano; James T Patrie; R Jeffrey Chang; Sonia Caprio; John C Marshall; Christopher R McCartney
Journal:  Obesity (Silver Spring)       Date:  2010-03-25       Impact factor: 5.002

4.  Associations between vitamin D levels and polycystic ovary syndrome phenotypes.

Authors:  Erin M Davis; Jennifer D Peck; Karl R Hansen; Barbara R Neas; LaTasha B Craig
Journal:  Minerva Endocrinol       Date:  2018-04-12       Impact factor: 2.184

5.  Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome.

Authors:  S A R Doi; M Al-Zaid; P A Towers; C J Scott; K A S Al-Shoumer
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

6.  Differential sleep-wake sensitivity of gonadotropin-releasing hormone secretion to progesterone inhibition in early pubertal girls.

Authors:  Jessicah S P Collins; John C Marshall; Christopher R McCartney
Journal:  Neuroendocrinology       Date:  2012-03-01       Impact factor: 4.914

7.  Single-cell expression analysis of BMP15 and GDF9 in mature oocytes and BMPR2 in cumulus cells of women with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation.

Authors:  Luciana Ochuiuto Teixeira de Resende; Alessandra Aparecida Vireque; Laura Ferreira Santana; Daniel Antunes Moreno; Ana Carolina Japur de Sá Rosa e Silva; Rui Alberto Ferriani; Carlos Alberto Scrideli; Rosana Maria Reis
Journal:  J Assist Reprod Genet       Date:  2012-07-24       Impact factor: 3.412

8.  Maturation of luteinizing hormone (gonadotropin-releasing hormone) secretion across puberty: evidence for altered regulation in obese peripubertal girls.

Authors:  Christopher R McCartney; Kathleen A Prendergast; Susan K Blank; Kristin D Helm; Sandhya Chhabra; John C Marshall
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

9.  Prenatal testosterone exposure induces hypertension in adult females via androgen receptor-dependent protein kinase Cδ-mediated mechanism.

Authors:  Chellakkan S Blesson; Vijayakumar Chinnathambi; Gary D Hankins; Chandra Yallampalli; Kunju Sathishkumar
Journal:  Hypertension       Date:  2014-12-08       Impact factor: 10.190

Review 10.  Nonhuman primate models of polycystic ovary syndrome.

Authors:  David H Abbott; Lindsey E Nicol; Jon E Levine; Ning Xu; Mark O Goodarzi; Daniel A Dumesic
Journal:  Mol Cell Endocrinol       Date:  2013-01-29       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.